ER ER ER ER - Endocrine Reviews

169. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL,
Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D,
Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC 2005 Preoperative
gefitinib versus gefitinib and anastrozole in postmenopausal patients with
oestrogen-receptor positive and epidermal-growth-factor-receptor-positive
primary breast cancer: a double-blind placebo-controlled phase II randomised
trial. Lancet Oncol 6:383-91
170. Winer E, Cobleigh MA, Dickler M, Miller K, Fehrenbacher L, Jones C,
Justice R 2002 Phase II multicenter study to evaluate the efficacy and safety of
Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced
or metastatic breast cancer. Breast Can. Res. Treat. 76:A445
171. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith
BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM 2001 The effects of the
novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase
inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines
in vitro and in vivo. Mol Cancer Ther 1:85-94
172. Spector NL, Xia W, Burris H, 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B,
Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A,
Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S 2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and
ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with
advanced malignancies. J Clin Oncol 23:2502-12
67